Global Allergic Asthma Therapeutics Market to Surpass US$ 8,209.0 Million by End of 2027, Says Coherent Market Insights

SEATTLE--()--According to Coherent Market Insights, the global allergic asthma therapeutics market is estimated to be valued at US$ 6,704.8 million in 2020 and is expected to rise at a CAGR of 2.93% during the forecast period (2020-2027).

Key Trends and Analysis:

The global allergic asthma therapeutics market is expected to witness significant growth owing to drug approvals and strategic collaborations among market players. For instance, Teva Pharmaceuticals Industries Limited, in June 2017, received the U.S. FDA approval for its two asthma inhalers, ArmonAir RespiClick and AirDuo RespiClick. These inhalers can be administered by an adult as well as adolescent asthma patients, which is available by prescription in the U.S. Such factors are expected to support the growth of allergic asthma therapeutics market size.

Furthermore, in May 2019, ASLAN Pharmaceuticals revised its license agreement with CSL Limited to obtain full global rights to develop, produce, and commercialize ASLAN004 for all indications. ASLAN004 helps in triggering the symptoms of allergic asthma such as coughing, shortness of breath, wheezing, and exacerbations of the disease.

Key players are focused on joint ventures for development of drugs which is expected to help the growth of the market. For instance, Regeneron Pharmaceuticals, Inc. and Sanofi jointly developed Dupixent (dupilumab) as an added maintenance therapy for moderate to severe asthma patients. They received the U.S. FDA approval in October 2018.

Request for Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/4019

Key Market Takeaways:

The global allergic asthma therapeutics market is expected to exhibit a CAGR of 2.9% during the forecast period (2020-2027) owing to collaborations among key players. For instance, in September 2019, Abionic and Genentech entered a joint agreement to develop and provide quick point-of-care tests for asthma in the U.S.

North America is projected to be the most lucrative region in the global allergic asthma therapeutics market owing to the presence of major industry players and FDA approvals of novel drugs. For instance, in September 2018, Novartis received the US Food and Drug Administration (FDA) approval for its prefilled syringe formulation, Xolair (omalizumab).

Key players operating in the global allergic asthma therapeutics market are

Aslan Pharmaceuticals Pte. Ltd., Baxalta Incorporated, Axikin Pharmaceuticals, Chiesi Farmaceutici SpA, CSL Limited, Circassia Pharmaceuticals Plc, Fountain Biopharma Inc., Hydra Biosciences, GlaxoSmithKline Plc, Infinity Pharmaceuticals, Mabtech Limited, Kineta, Marinomed Biotechnologie Gmb, NeoPharm Co., Mycenax Biotech Inc., Panacea Biotec Limited, and Oxagen Limited.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4019

Market Segmentation:

  • Global Allergic Asthma Therapeutics Market, By Drug Type:
    • Corticosteroids
    • Bronchodilators
    • Leukotriene modifiers
    • Immunotherapy
    • Biologics
    • Others
  • Global Allergic Asthma Therapeutics Market, By Route of Administration:
    • Oral
    • Inhaled
    • Others
  • Global Allergic Asthma Therapeutics Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Report:

Asthma & COPD Market, By Drug Type (Bronchodilators (Short Acting Bronchodilators, Long Acting Bronchodilators, Anticholinergics), Anti-Inflammatories (Inhaled Corticosteroids, Anti-Leukotriene, Monoclonal Antibodies), Combination Therapies), By Disease Type (Asthma, COPD), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores), and By Region (North America, Latin America, Europe Asia, Pacific Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Read more: https://www.coherentmarketinsights.com/market-insight/asthma-and-copd-market-4002

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

Release Summary

North America is projected to be the most lucrative region in the global allergic asthma therapeutics market.

Contacts

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter